Wall Street analysts expect that Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) will post earnings per share of ($0.56) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Rhythm Pharmaceuticals’ earnings. The highest EPS estimate is ($0.46) and the lowest is ($0.65). Rhythm Pharmaceuticals posted earnings per share of ($0.41) in the same quarter last year, which indicates a negative year over year growth rate of 36.6%. The company is scheduled to report its next quarterly earnings report on Monday, March 11th.
On average, analysts expect that Rhythm Pharmaceuticals will report full-year earnings of ($2.20) per share for the current fiscal year, with EPS estimates ranging from ($2.29) to ($2.10). For the next financial year, analysts expect that the firm will report earnings of ($2.56) per share, with EPS estimates ranging from ($3.66) to ($1.93). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that follow Rhythm Pharmaceuticals.
Several research firms recently issued reports on RYTM. BidaskClub upgraded shares of Rhythm Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday. Stifel Nicolaus reiterated a “hold” rating and set a $36.00 price target on shares of Rhythm Pharmaceuticals in a research report on Sunday, November 11th. ValuEngine upgraded shares of Rhythm Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, October 17th. Needham & Company LLC set a $42.00 price target on shares of Rhythm Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, December 14th. Finally, Zacks Investment Research lowered shares of Rhythm Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $38.25.
Several hedge funds and other institutional investors have recently bought and sold shares of RYTM. Geode Capital Management LLC boosted its position in Rhythm Pharmaceuticals by 30.2% in the fourth quarter. Geode Capital Management LLC now owns 233,894 shares of the company’s stock valued at $6,287,000 after buying an additional 54,247 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in Rhythm Pharmaceuticals in the fourth quarter valued at approximately $1,447,000. Great West Life Assurance Co. Can acquired a new stake in Rhythm Pharmaceuticals in the fourth quarter valued at approximately $68,000. Emory University acquired a new stake in Rhythm Pharmaceuticals in the fourth quarter valued at approximately $2,225,000. Finally, Citigroup Inc. boosted its position in Rhythm Pharmaceuticals by 147.5% in the fourth quarter. Citigroup Inc. now owns 67,903 shares of the company’s stock valued at $1,825,000 after buying an additional 40,469 shares in the last quarter. Institutional investors and hedge funds own 90.56% of the company’s stock.
Shares of NASDAQ RYTM traded up $0.07 during trading hours on Wednesday, hitting $29.78. 36,400 shares of the stock were exchanged, compared to its average volume of 88,540. The firm has a market capitalization of $975.54 million, a price-to-earnings ratio of -10.52 and a beta of 1.41. Rhythm Pharmaceuticals has a 1-year low of $16.80 and a 1-year high of $37.23.
Rhythm Pharmaceuticals Company Profile
Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its peptide candidates include Setmelanotide, a melanocortin-4 receptor agonist, which is in Phase III clinical trial to treat POMC and leptin receptor deficiency obesity; and Phase II clinical trial for Bardet-Biedl and Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders.
Recommended Story: Bond
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.